Novartis plans US launch of indacaterol inhaler following US thumbs up
This article was originally published in Scrip
Executive Summary
Novartis is planning the US launch of its long-acting beta2-agonist (LABA), Arcapta Neohaler (indacaterol inhalation powder), for chronic obstructive pulmonary disease (COPD) in the first quarter of 2012 after receiving marketing authorisation for the product from the US FDA.